Biotech Values

[DewDiligence]

(AMGN/FGEB)—Roxadustat, a pill which may not require additional iron, sounds to me like an epo-killer.
What am I missing?

I was referring to AMGN, specifically, in reply to the question in #msg-144032522. For AMGN specifically, there's less and less EPO to be killed with each passing day, so AMGN investors are not unduly concerned about losing EPO sales to a new drug class.

On the other hand, the overall market for EPO drugs (including knockoffs and bona fide biosimilars) is clearly large enough to be an attractive target for companies such as FGEN.